T-DM1 Boosts Survival in HER2-Positive Breast Cancer ...Middle East

Medscape - News
T-DM1 Boosts Survival in HER2-Positive Breast Cancer
Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly assigned to receive either T-DM1 or trastuzumab for 14 cycles. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( T-DM1 Boosts Survival in HER2-Positive Breast Cancer )

Apple Storegoogle play

Also on site :



Latest News